LTRN — Lantern Pharma Share News
0.000.00%
Last trade - 00:00Lantern Pharma Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Lantern Pharma Confirms No Exposure To Silicon Valley Bank, Silvergate Bank, Or Signature Bank
Brief: Lantern Pharma Announces New Data And Development Focus For Lp-100 With Parp Inhibitors
Brief: Lantern Pharma Announces Formation Of Starlight Therapeutics To Advance Transformative Therapies For Central Nervous System and Brain Cancers
Lantern Pharma Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Lantern Pharma Expands Clinical Leadership Team To Further Advance Its Ongoing And Upcoming Clinical Trials
Brief: Lantern Pharma And Ttc Oncology Establish Ai Collaboration To Expand The Clinical Development Of Drug Candidate Ttc-352
Brief: Lantern Pharma Inc. - Announced Expansions And Updates To RADR's Product Roadmap
U.S. STOCKS ON THE MOVE-Chord Energy, Kroger, PetMed Express
U.S. STOCKS ON THE MOVE-DoorDash, Walt Disney, Tesla
Brief: Lantern Pharma Receives Pre-IND Feedback From FDA, Clearing Path For Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023
U.S. STOCKS ON THE MOVE-Papa John's, Whirlpool, Coca-Cola
Lantern Pharma rises on FDA guidance for cancer drug trials
Brief: FDA Grants Lantern Pharma Orphan Drug Designation For LP-284
Lantern Pharma up on positive pre-clinical data of cancer drug
Brief: Lantern Pharma Announces Positive New Data For Its Drug Candidate LP-284
U.S. STOCKS ON THE MOVE-Caterpillar, Coinbase, WW International
Lantern Pharma up after positive data on brain cancer drug candidate
Brief: Lantern Pharma Announces Positive Data Highlighting The Anti-Tumor Potency Of Drug Candidate Lp-184 For Glioblastoma At The Society For Neuro-Oncology Annual Meeting